Delcath Systems to Present at Canaccord Adams 29th Annual Global Growth Conference

View printer-friendly version

NEW YORK, Aug. 10 -- Delcath Systems, Inc. (Nasdaq: DCTH), a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, today announced its President and CEO Eamonn P. Hobbs will make a presentation to investors at the Canaccord Adams 29th Annual Global Growth Conference on Thursday, August 13 at 9:30 a.m. Eastern Time in Boston. Mr. Hobbs will review the company's business strategy and historic financial results.

Attendance at the conference is by invitation only. Delcath Systems will offer a live webcast of its presentation and an archived replay available for 90 days at

About Delcath Systems, Inc.
Delcath Systems, Inc. is a medical device company specializing in cancer treatment. The Company is testing a proprietary, patented drug delivery system for the treatment of liver cancers. Delcath's novel drug delivery platform is testing the delivery of ultra-high doses of anti-cancer drugs to the liver while preventing these high doses of drug from entering the patient's bloodstream. The Company is currently enrolling patients in Phase III and Phase II clinical studies for the treatment of liver cancers using high doses of melphalan. The Company's intellectual property portfolio consists of twenty-seven patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at

This Site contains information and press releases about us. This information should be considered accurate only as of the date prepared. You acknowledge that this information may change over time and you should not assume that the information is accurate at a later date. Delcath Systems, Inc. is not obligated to update the press releases and information contained in this section of the Site.